Thermo Fisher Underscores Allergy Test Opportunity With $3.5 Bil. Phadia Deal

Thermo Fisher Scientific wants to claim a dominant share of the budding in vitro allergy testing market segment in the U.S. with its planned $3.5 billion acquisition of Swedish firm Phadia, announced May 19.